Patents Represented by Attorney Francis J. Tinney
-
Patent number: 5929064Abstract: Amino acid complexes of cobalt (III) mesoporphyrin IX and cobalt (III) protoporphyrin IX are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as antiobesity agents and for the treatment of cyanide poisoning, neonatal hyperbilirubinemia, and cancer.Type: GrantFiled: February 2, 1998Date of Patent: July 27, 1999Assignee: Warner-Lambert CompanyInventors: Om P. Goel, Stephen J. Johnson, Lawrence D. Wise
-
Patent number: 5919780Abstract: Compounds of formula I ##STR1## wherein X is N or C--R.sup.9, Y is N--R.sup.10, CH.sub.2, O, S, SO, SO.sub.2, C.dbd.O or CH--OH,R is H or alkyl,R.sup.1 is heteroaryl,n is 1-5, andR.sup.2 -R.sup.10 are H or various substituents,are useful as inhibitors of protein farnesyl transferase and for the treatment of proliferative diseases including cancer, restenosis and psoriasis, and as antiviral agents.Type: GrantFiled: December 11, 1997Date of Patent: July 6, 1999Assignee: Warner Lambert CompanyInventors: Gary L. Bolton, Annette M Doherty, James S. Kaltenbronn, John Quin, III, Jeffrey D. Scholten, Judith Sebolt-Leopold, Harold Zinnes
-
Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
Patent number: 5908923Abstract: A method of using a transdominant negative integrase gene to make at least one cell resistant to a retroviral infection which includes retroviral infections resulting from HIV; a method for introducing a transdominant negative integrase gene into at least one mammalian cell to make said cell resistant to a retroviral infection as well as vectors, cells, and methods of constructing same useful in the aforementioned methods; a method of treating AIDS comprising administering to a patient an effective amount of a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2; and pharmaceutical delivery methods which include a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2.Type: GrantFiled: April 29, 1997Date of Patent: June 1, 1999Assignee: Warner-Lambert CompanyInventors: Tod Paul Holler, Annette Meyer, Gary Jan Nabel, Leonard Post -
Patent number: 5869579Abstract: A method for the solid phase preparation of an amine by a novel synthesis is described where a diol is monoalkylated with a chloromethyl resin followed by reaction with N,N'-carbonyldimidazole to afford a resin-bound tertiary-alkoxycarbonyl-imidazole which is subsequently N-alkylated and then sequentially treated with appropriate building blocks and reagents to afford a resin-bound amine which affords the desired amine after treatment with an acid as well as other valuable intermediates used in the process.Type: GrantFiled: November 6, 1997Date of Patent: February 9, 1999Assignee: Warner-Lambert CompanyInventors: John Cooke Hodges, Andres Sergio Hernandez
-
Patent number: 5773444Abstract: Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.Type: GrantFiled: April 14, 1997Date of Patent: June 30, 1998Assignee: Warner-Lambert CompanyInventors: Kyunghye Ahn, Xue-Min Cheng, Annette Marian Doherty, Edward Faith Elslager, Brian Kornberg, Chitase Lee, Daniele Leonard, Sham Nikam, Leslie Morton Werbel
-
Patent number: 5773414Abstract: Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.Type: GrantFiled: March 7, 1997Date of Patent: June 30, 1998Assignee: Warner-Lambert CompanyInventors: Wayne Livingston Cody, Patricia DePue, Annette Marian Doherty, John Xiaoqiang He, Michael Douglas Taylor
-
Patent number: 5766556Abstract: An apparatus and method which provides a suitable location for multiple, simultaneous synthesis of compounds. The apparatus consists of: a reservoir block having a plurality of wells; a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends; a holder block, having a plurality of apertures; and a manifold, which may have ports to allow introduction/maintenance of a controlled environment. The manifold top wall has apertures and a detachable plate with identical apertures. The apparatus is constructed from materials which will accommodate heating, cooling, agitation, or corrosive reagents. Gaskets are placed between the components. Rods or clamps are provided for fastening the components together. Apparatus operation involves placing the filters on the lower ends of the reaction tubes in the reservoir block wells, and the upper ends passing through the holder block apertures and into the manifold.Type: GrantFiled: December 31, 1996Date of Patent: June 16, 1998Assignee: Warner-Lambert CompanyInventors: Sheila Helen Hobbs DeWitt, John Steven Kiely, Michael Raymond Pavia, Mel Conrad Schroeder, Charles John Stankovic
-
Patent number: 5721266Abstract: Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of N,N'-piperazinylbis-?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!.Type: GrantFiled: September 26, 1994Date of Patent: February 24, 1998Assignee: Warner-Lambert CompanyInventors: Stuart James Decker, David William Fry, James Marino Hamby, Alan Robert Saltiel
-
Patent number: 5714127Abstract: A system for the multiple, simultaneous synthesis of compounds preferably uses a reaction apparatus comprising a reservoir rack having a plurality of reaction wells, a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends, a holder block, having a plurality of apertures, and a manifold, which has ports to allow introduction/maintenance of a controlled environment. The manifold top wall has a plurality of apertures in axial alignment with the reaction tubes and a gasket which allows penetration by a needle in order to dispense and aspirate materials from the reaction tubes. Sealing members, such as gaskets, are placed between the holder block, manifold and reservoir rack and the components are releasably fastened together. A robotic sample processor is used to automate the synthesis process using the reaction apparatus.Type: GrantFiled: June 7, 1995Date of Patent: February 3, 1998Assignee: Warner-Lambert CompanyInventors: Sheila H. H. DeWitt, John S. Kiely, Michael R. Pavia, Mel C. Schroeder, Charles J. Stankovic
-
Patent number: 5710277Abstract: An improved process for the preparation of R(+)1,2,3,6-tetrahydro-4-phenyl-1-?(3-phenyl-3-cyclohexen-1-yl)methyl!pyri dine by a novel synthesis is described where 5-oxo-3-phenyl-3-cyclohexene-carboxylic acid is converted in five operations to the desired product, as well as processes for the resolution of 5-oxo-3-phenyl-3-cyclohexenecarboxylic acid using cinchonidine to afford (S)5-oxo-3-phenyl-3-cyclohexenecarboylic acid or .alpha.-chymotrypsin to selectively hydrolyze n-butyl 5-oxo-3-phenyl-3-cycohexenecarboxylate to afford (S)5-oxo-3-phenyl-3-cyclohexenecarboxylic acid as well as other valuable intermediates used in the processes.Type: GrantFiled: September 12, 1994Date of Patent: January 20, 1998Assignee: Warner-Lambert CompanyInventors: Donald Eugene Butler, Jodette Gailey, Tung Van Le, William John Smith, III, David Juergen Wustrow
-
Patent number: 5693845Abstract: Novel cyanocycloalkylacetic acids and esters as well as salts thereof and in particular 1-cyanocyclohexaneacetic acid and ethyl 1-cyanocyclohexaneacetate are described which are useful as intermediates in a process for the preparation of cyclic amino acids.Type: GrantFiled: March 6, 1992Date of Patent: December 2, 1997Assignee: Warner-Lambert CompanyInventors: Rex Allen Jennings, Don Richard Johnson, Ronald Everett Seamans, James Robert Zeller
-
Patent number: 5679683Abstract: Novel 4-substituted amino benzothieno?3,2-d!pyrimidine and 4-substituted amino?2,3-d!pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.Type: GrantFiled: December 23, 1994Date of Patent: October 21, 1997Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Howard Daniel Hollis Showalter
-
Patent number: 5665764Abstract: Tricyclic compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, cancer metastasis, tumor angionenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.Type: GrantFiled: June 2, 1995Date of Patent: September 9, 1997Assignee: Warner-Lambert CompanyInventors: Donald Hupe, Linda Lea Johnson, Joseph Armand Picard, Andrew David White, Qi-Zhuang Ye
-
Patent number: 5663296Abstract: Hydroxamate compounds of the following formula are disclosed:R--AA.sup.3 --AA.sup.4 --AA.sup.5 --AA.sup.6 --NH--OR.sup.2wherein AA.sup.3 --AA.sup.6 represent amino acid residues. The disclosed compounds are inhibitors of endothelin converting enzyme, and as such are useful for the treatment of disorders resulting from overproduction of endothelin, i.e., acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestire heart failure, endotoxic shock and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, cerebral vasospasm, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.Type: GrantFiled: January 17, 1995Date of Patent: September 2, 1997Assignee: Warner-Lambert CompanyInventors: Annette Marian Doherty, Brian Edward Kornberg, Sham Nikam
-
Patent number: 5658902Abstract: Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.Type: GrantFiled: December 22, 1994Date of Patent: August 19, 1997Assignee: Warner-Lambert CompanyInventors: Kyunghye Ahn, Xue-Min Cheng, Annette Marian Doherty, Edward Faith Elslager, Brian Kornberg, Chitase Lee, Daniele Leonard, Sham Nikam, Leslie Morton Werbel
-
Patent number: 5654307Abstract: Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.Type: GrantFiled: December 23, 1994Date of Patent: August 5, 1997Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson
-
Patent number: 5646027Abstract: A process for the production of the catalytic domain, without propeptide, C-terminal domain, and the fibronectin-like insert, of human gelatinases is described which comprises culturing transformed E. coli host cells carrying a synthetic DNA sequence encoding the catalytic domain as well as a method for screening for inhibitors of a gelatinase; a method for determining the 3-dimensional structure of the catalytic domain of a gelatinase; and pharmaceutical compositions of human gelatinase catalytic domain protein which are useful in treating herniated vertebral discs, dermal ulcers, modifying scar tissue formation, and joint diseases.Type: GrantFiled: September 8, 1994Date of Patent: July 8, 1997Assignee: Warner-Lambert CompanyInventors: Qi-Zhuang Ye, Linda Lea Johnson, Donald John Hupe
-
Patent number: 5641752Abstract: Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.Type: GrantFiled: September 30, 1994Date of Patent: June 24, 1997Assignee: Warner-Lambert CompanyInventors: Wayne Livingston Cody, Patricia DePue, Annette Marian Doherty, John Xiaoqiang He, Michael Douglas Taylor
-
Patent number: 5627206Abstract: A tricyclic compound is described as well as pharmaceutical compositions of same, which is useful as an inhibitor of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) for the treatment of multiple sclerosis or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.Type: GrantFiled: June 2, 1995Date of Patent: May 6, 1997Assignee: Warner-Lambert CompanyInventors: Donald Hupe, Linda Lea Johnson, Qi-Zhuang Ye
-
Patent number: 5620988Abstract: Substituted tetrahydropyridines and hydroxypiperidines and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.Type: GrantFiled: June 6, 1995Date of Patent: April 15, 1997Assignee: Warner-Lambert CompanyInventors: Shelly Glase, Juan C. Jaen, Sarah J. Smith, Lawrence D. Wise